To the Editor: In their Commentary, Drs Hingorani and Psaty1 invoked the prevention paradox (a large proportion of cardiovascular disease [CVD] events occur among the many individuals with average risk factor values) in their discussion of whether to embrace new CVD risk markers as tools for targeting or personalizing statin therapy. They also described another well-known apparent paradox: even risk markers that are strongly associated with the outcome of interest (relative risks of 3 to 5 or even larger) often seem to contribute little in terms of discrimination or reclassification.2
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 2
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.